Henlius Swallows Bitter Pill in Watered-Down Licensing Deal 對外授權訂單縮水 復宏漢霖「出海」遇阻？
The innovative drug company will receive less benefits from an existing licensing deal after revisions to reflect high R&D costs 這家創新藥企業的一項授權合作的最高收入將會減少，爲股價帶來負面影響。
Bamboo Works (official website) provides news on Chinese companies listed in Hong Kong and the United States, with a strong focus on mid-cap and also pre-IPO companies.